MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

The following is a summary of “Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Under the terms of the agreement, Eagle will receive $69 million before transaction costs as an upfront payment in exchange for a prespecified amount of Eagle’s royalty interest for net sales of ...

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

The company needs to win over haematologists to its new treatment, as biosimilar versions of rituximab are expected to hit the European market in 2017, and could be close behind in the US.

One of these therapies, rituximab, a chimeric monoclonal antibody against human CD20 (hCD20; a B-cell-specific surface marker), depletes B cells and has been effective in several autoimmune ...

Eagle Pharmaceuticals (EGRX) announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...